Johnson & Johnson (NYSE:JNJ) posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.
Johnson & Johnson reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.74 billion, up 5.8% year over year and beating the consensus of $22.85 billion.
